Diagnosis and Management of Acquired Hemophilia A: Case Reports and a Literature Review

Table 1

Summary of hemostatic therapies found in the literature.

Therapy	Authors
	Tiede et al. [16]	Kruse-Jarres et al. [6]	Shetty et al. [17]
Human factor VIII	50–100 U/kg followed by tailored dosing; If other options are unavailable	Dose not mentioned	Dose not mentioned
Recombinant porcine factor VIII (rpFVIII)	200 U/kg, followed by further doses to maintain levels >50%	If no antiporcine FVIII inhibitors present, 50–100 U/kg initially while monitoring FVIII activity every 2-3 h, with dose adjusted as required; If antiporcine FVIII inhibitors are detected, 200 U/kg initially for severe bleeding or 50–100 U/kg for less severe bleeding	Not mentioned
Recombinant FVII activated (rFVIIa)	Bolus injections of 90 μg/kg every 2-3 h until hemostasis is achieved	Dose of 70–90 μg/kg every 2-3 h until hemostasis achieved	90 mcg/kg every 2 h until bleeding has been controlled
Activated prothrombin complex concentrate (APCC)	Bolus injections of 50−100 U/kg every 8−12 h, up to a maximum of 200 U/kg/day	Dose of 50–100 U/kg every 8–12 h not exceeding 200 U/kg/day	50–100 U/kg every 8–12 h with a maximum dose of 200 U/kg/day